We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Kyowa Hakko Kirin

News List

Kyowa Hakko Kirin signs AI drug R&D deal with InveniAI pharmaphorum
January 14, 2019
Artificial intelligence and machine learning company InveniAI has joined with Kyowa Hakko Kirin to harness the power of technology for drug discovery.
Lancet publishes PhIII data on Kyowa Hakko’s Poteligeo pharmatimes
August 16, 2018
The Lancet has published data from Kyowa Hakko Kirin Co’s successful Phase III trial of immunotherapy Poteligeo underpinning its recent approval in the US to treat in patients with cutaneous T-cell lymphoma (CTCL).
Kyowa Hakko Kirin announces results of Phase 3 trial of patients with Cutaneous T-cell Lymphoma biospectrumasia
August 14, 2018
MAVORIC study (Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In CTCL) investigating the use of mogamulizumab in patients with cutaneous T-cell lymphoma (CTCL) have been published in Lancet Oncology.
FDA Grants Breakthrough Therapy Designation for Mogamulizumab americanpharmaceuticalreview
August 28, 2017
Kyowa Hakko Kirin announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to their investigational product, mogamulizumab which is being developed for the treatment of Mycosis Fungoides (MF) and Sézary Syn